NCT07256015 Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
| NCT ID | NCT07256015 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bristol-Myers Squibb |
| Condition | Psoriasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-08-05 |
| Primary Completion | 2027-07-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-08-05 with a primary completion date of 2027-07-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy
Eligibility Criteria
Inclusion Criteria: * Participants have initiated treatment with deucravacitinib monotherapy 4 to 8 weeks earlier according to clinical practice and to reimbursement criteria determined by National Drug Agency in Italy (AIFA) * Patients have moderate to severe plaque psoriasis * Patients have signed informed consent form (ICF) Exclusion Criteria: * Simultaneous participation in any interventional study for their moderate-to-severe psoriasis * Inability to participate to the study for the following reasons: patients unable to understand the aim of the study, patients unable to understand and sign the ICF
Contact & Investigator
Bristol Myers Squibb
STUDY DIRECTOR
Bristol-Myers Squibb
Frequently Asked Questions
Who can join the NCT07256015 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07256015 currently recruiting?
Yes, NCT07256015 is actively recruiting participants. Contact the research team at Clinical.Trials@bms.com for enrollment information.
Where is the NCT07256015 trial being conducted?
This trial is being conducted at Verona, Italy.
Who is sponsoring the NCT07256015 clinical trial?
NCT07256015 is sponsored by Bristol-Myers Squibb. The principal investigator is Bristol Myers Squibb at Bristol-Myers Squibb. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.